Latest Peyronie's disease Stories
LYNBROOK, N.Y., Nov. 3, 2014 /PRNewswire/ -- BioSpecifics Technologies Corp.
Multiple Presentations Designed to Enable a Better Understanding of the Safety and Efficacy Profile of XIAFLEX for Treatment of Peyronie's Disease CHESTERBROOK, Pa., Nov.
- Label expansion to broaden patient base who may benefit from nonsurgical collagenase therapy LYNBROOK, N.Y., Oct.
Estimated 35-40 Percent of Surgical Procedures to Treat DC Have Been Performed on Multiple Joints CHESTERBROOK, Pa., Oct.
LYNBROOK, N.Y., Oct. 8, 2014 /PRNewswire/ -- BioSpecifics Technologies Corp.
Erectile Dysfunction in Younger and Older Men Has Many Overlooked Causes. NEW YORK, Sept.
LYNBROOK, N.Y., Sept. 19, 2014 /PRNewswire/ -- BioSpecifics Technologies Corp.
- Data suggest support for potential label expansion of XIAFLEX for Dupuytren's contracture to include treatment of two affected joints concurrently; PDUFA date is October 20, 2014 - LYNBROOK,
Data Support CCH could be Used to Treat Two Affected Joints Concurrently; Positive Results Presented from Additional Studies Evaluating CCH Retreatment for Recurrent Contracture CHESTERBROOK,
Study Results of Concurrent CCH Injections to Treat Two Dupuytren's Contracture Cords with Delayed Finger Extension Selected for Best Paper Session; Data Support Safe and Effective Use of CCH for Treatment